Jpmorgan Chase & CO Adicet Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 771 shares of ACET stock, worth $971. This represents 0.0% of its overall portfolio holdings.
Number of Shares
771
Previous 59,243
98.7%
Holding current value
$971
Previous $139,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ACET
# of Institutions
92Shares Held
66.3MCall Options Held
4.3KPut Options Held
36.3K-
Orbimed Advisors LLC San Diego, CA11.4MShares$14.4 Million0.33% of portfolio
-
Tang Capital Management LLC San Diego, CA8.22MShares$10.4 Million1.21% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.54MShares$9.5 Million0.14% of portfolio
-
Goldman Sachs Group Inc New York, NY4.28MShares$5.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.62MShares$4.56 Million0.0% of portfolio
About Adicet Bio, Inc.
- Ticker ACET
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,030,800
- Market Cap $50.4M
- Description
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...